Method for correction of blood microvesicle level in arterial hypertension

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology and cardiology, and concerns correction of blood microvesicle level in arterial hypertension. That is ensured by introduction of lisinopril in a dose 10 mg once in the morning and amlodipine in a dose 5 mg once in the morning within at least 5 weeks. Introduction of specific preparations throughout empirically specified time of treatment ensures complete normalisation of blood microvesicle level.

EFFECT: invention allows reducing risk of thrombotic complications in given group of patients.

1 ex

 

The invention relates to medicine, namely to Hematology and cardiology.

Analogues of the proposed method of correction of the level of microvesicles in the blood with arterial hypertension (AH) does not exist.

It is known that an important feature of the cytoplasmic membrane is asymmetric phospholipid and protein composition of the two leaflets of the bilayer, which occurs under the action of intracellular enzymes, differences in the ionic composition of the cytoplasm and the extracellular fluid. The asymmetry of the bilayer determines thrombogenicity and hemocoagulation properties of blood cells and endothelium of blood vessels and, in addition, participates in the creation of the gradient of curvature of the folds, morsiani, outsoruce areas of the membrane in the form of microvesicles.

Formed by exocytosis, necrosis and apoptosis fragments of cell membranes are able to withdraw and form bubbles with a diameter of from 0.05 to 3.0 μm. The size of the microvesicles depends on the nature of the agent acting on the target cell. Microvesicles are platelet and nitrobacteria origin. They are formed on the cell surface, lusiwasi with the cytoplasmic membrane. Therefore, they contain various membrane glycoproteins, proteins of the cytoskeleton, fibers, chains of myosin, etc.

Microvesicles are not only of a catalytic surface for the inner "ten the threat" (supramolecular complex, consisting of factor IXa, factor VIIIa, and phospholipids) and prothrombinase complex, but also able to influence the proteolytic inactivation of factors Va and VIIIa by activated protein C in combination with protein S. Therefore reducing the level of microvesicles in the blood leads to reduction of hemocoagulation potential estramboticos blood plasma.

When AG increased blood level of microvesicles, causing the increase of coagulation opportunities plasma. However, approaches to reduce the level of microvesicles in the blood remain very poorly developed. When AG such approaches has not previously been used. In patients with hypertension to lower blood pressure are applied ACE inhibitors and calcium antagonists (B.C. Zadionchenko and other Arterial hypertension in the metabolic syndrome: pathogenesis, therapy basics". Consilium medicum 2004, Vol.6, No. 9, http://www.voed.ru/art.gip.metab.sindr.htm).

However, never before medical complex consisting of lisinopril and amlodipine has been used in patients to reduce the level of microvesicles.

The aim of the invention is the lowering of the level of microvesicles in the blood of patients with hypertension.

The essence of the proposed method lies in the fact that for the correction of the level of microvesicles in the blood of patients with hypertension for at least 5 weeks is prescribed lisinopril 10 mg 1 every morning and amlodipine 5 mg 1 time in the morning.

The method provides the correct level of microvesicles in the blood of patients with hypertension for at least 5 weeks, putting it on a level close to that of healthy people. Subject to the subsequent recommendations of the proposed method it is possible to maintain the level of microvesicles at the optimal level, which will significantly reduce the risk of thrombotic complications, reduce the number of cases of temporary disability, to expedite patient treatment and improve the quality, reduce disability, and also to prolong the life and reduce mortality of patients with hypertension from heart attack and stroke.

The inventive method is carried out as follows.

Establishing the level of blood microvesicles carry out activity 5-nucleotidase in serum (Ldzierba, Dimswart, Ihantola and other Cellular microvesicles in the dynamics of experimental endotoxinemia. // Bulletin of experimental biology and medicine: monthly international scientific-theoretical journal of the Russian Academy of medical Sciences, 2006, Tom, No. 11, S-520). OK its level representing 63.8±2,5 ncat. When the level of microvesicles in the blood of patients with hypertension should prescribe lisinopril 10 mg 1 every morning and amlodipine 5 mg 1 time in the morning.

Example. Patient C., 45 years old, with hypertension grade 2, stage 2 with blood pressure 165/100 mm Hg during examination revealed an increased level of microvesicles in blood plasma 126,4 ncat. The patient was prescribed lisinopril 10 mg 1 every morning and amlodipine 5 mg time in the morning. The patient was regularly looked after the start of treatment. Simultaneously with the inspection was carried out to determine the level of blood microvesicles.

After 5 weeks of treatment, the patient's blood pressure stabilized at the level of 120/80 mm Hg at normal levels, blood microvesicles average of 60.5 ncat.

The patient is asked to comply with these recommendations in future.

The use of the proposed method of correction of the level of microvesicles blood Hematology and cardiology will help to avoid many of the vascular complications in patients with hypertension, to reduce their number of cases of temporary disability, to reduce the duration of hospitalization, reduce morbidity and mortality.

The correction method of the level of microvesicles in the blood in hypertension through the use of lisinopril 10 mg 1 every morning and amlodipine 5 mg 1 every morning for at least 5 weeks.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns correction of blood microvesicle level in arterial hypertension with impaired glucose tolerance. That is ensured by integrated treatment including graduated physical exercises, and introduction of Fosinopril in a dose 10 mg once in the morning and pioglitazone in a dose 30 mg once in the morning. Therapeutic course is at least 7 weeks.

EFFECT: complex of drug-free modalities and specific pharmacological preparations combined with empirically specified time of treatment provides maintained optimum microvesicle level that in turn allows considerably reducing risk of thrombotic complications in given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology and concerns correction of blood microvesicle level in arterial hypertension (AH) and pancreatic diabetes type II (PD II). That is ensured by integrated therapy involving graduated physical exercises, as well as introduction of lisinopril in a dose 10 mg once in the morning, amlodipine in a dose 5 mg once in the morning and pioglitazone in a dose 30 mg once in the morning for therapeutic course at least 7 weeks.

EFFECT: complex of specific medical preparations and physical exercises combined with empirically specified duration of treatment provides effective correction of blood microvesicle level and, thereby, reduced risk of thrombotic complications in given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology and endocrinology, and concerns normalisation of thrombocyte sensitivity to aggregation inducers in patients suffering from arterial hypertension with impaired glucose tolerance. That is ensured by integrated therapy including graduated physical exercises, and introduction of lisinopril in a dose 10 mg once a day in the morning and pioglitazone in a dose 30 mg once a day in the morning. Therapeutic course lasts for at least 6 weeks. The method enables complete normalisation of thrombocyte sensitivity to aggregation inducers owing to potentiation of therapeutic effect of certain components of integrated therapy.

EFFECT: that in turn allows reducing risk of thrombotic complications in given group of patients.

1 ex, 3 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology, and covers correction of thrombocyte intravascular activity in patients suffering from arterial hypertension with impaired glucose tolerance. It is ensured by integrated treatment including graduated static and dynamic loading, and introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning.

EFFECT: such complex of specific medical agents and physical activity provides short-term - within 1,5 months - normalisation of thrombocyte intravascular activity that in turn reduces risk of thrombotic complications in given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns normalisation of lipid content in thrombocyte membranes in arterial hypertension and impaired glucose tolerance. That is ensured by integrated treatment including graduated physical exercise, and introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during 1.5 months.

EFFECT: such complex of specific medical agents and physical activity combined with empirically selected duration of treatment provides effective correction of lipid composition of thrombocyte membranes and thereby reduced risk of thrombotic complications in given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns normalisation of thrombocyte aggregation in patients suffering from arterial hypertension with impaired glucose tolerance. It is ensured by integrated treatment including graduated physical exercise, and introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during not less than 1.5 months.

EFFECT: such complex of specific medical products and physical exercise combined with empirically selected duration of treatment provides effective correction of thrombocyte aggregation and, thereby reduced risk of thrombotic complications in given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, and covers thrombocyte normalisation of ADP and ATP secretion in patients with arterial hypertension and impaired glucose tolerance. It is ensured by integrated treatment including graduated physical exercise, introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning.

EFFECT: such complex of specific pharmacological preparations and drug-free modalities provide complete thrombocyte normalisation of ADP and ATP secretion within 1,5 months that in turn allows normalising thrombocyte function in this group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns normalising endotheliocytemia in arterial hypertension with impaired glucose tolerance. It is ensured by complex therapy that involves graduated physical activities, as well as introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during 1.5 months.

EFFECT: invention provides effective correction of endotheliocytemia owing to potentiation of therapeutic effect of certain components of the complex therapy; than in turn allows reducing risk of thrombotic complications in the given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology, and covers hyperfibrinogenemia correction in arterial hypertension with impaired glucose tolerance. It is ensured by complex treatment that involves graduated physical activities, as well as introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during 1.5 months.

EFFECT: invention provides effective correction of fibrinogen level that is ensured by potentiation of therapeutic effect of certain components of complex therapy; than in turn allows reducing risk of thrombotic complications in the given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology, and covers correction of blood microvesicle level in arterial hypertension, dyslipidemia and impaired glucose tolerance. It is ensured by complex treatment that involves introduction of fozinopril in a dose 10 mg once a day in the morning, pioglitazone in a dose 30 mg once a day in the morning, simvastatin in a dose 40 mg in the evening in combination with graduated physical activities for therapeutic course at least 6 weeks.

EFFECT: invention provides complete normalisation of blood microvesicle level ensured by potentiation of therapeutic effect of certain components of the complex therapy; that in turn allows reducing risk of thrombotic in the given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology and concerns correction of blood microvesicle level in arterial hypertension (AH) and pancreatic diabetes type II (PD II). That is ensured by integrated therapy involving graduated physical exercises, as well as introduction of lisinopril in a dose 10 mg once in the morning, amlodipine in a dose 5 mg once in the morning and pioglitazone in a dose 30 mg once in the morning for therapeutic course at least 7 weeks.

EFFECT: complex of specific medical preparations and physical exercises combined with empirically specified duration of treatment provides effective correction of blood microvesicle level and, thereby, reduced risk of thrombotic complications in given group of patients.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 5-methoxy-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-6-methyl-3H-imidazo[4,5-b]pyridine or to its salt, as well as a pharmaceutical composition which inhibits secretion of gastric acid based on the said compound. Description is given of production of the new compound and a pharmaceutical composition based on the new compound, which can be used in medicine for treating such diseases as gastric ulcer, duodenal ulcer, stomal ulcer, gastroesophageal reflux, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux, endoscopy negative gastroesophageal reflux, gastroesophageal regurgitation, pharyngolaryngeal paresthesia, Barrett's esophagus, Non-steroidal anti-inflammatory drug (NSAID) induced ulcer, gastritis, gastric hemorrhage, gastrointestinal hemorrhage, peptic ulcer, bleeding ulcer, stress ulcer, gastric hyperchlorhydria, dyspepsia, gastroparesis, senile ulcer, intractable ulcer, heartburn, bruxism, stomach ache, heavy stomach or erosive gastritis.

EFFECT: increased effectiveness of composition and disease treatment.

7 cl, 6 tbl, 29 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 5-methoxy-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-6-methyl-3H-imidazo[4,5-b]pyridine or to its salt, as well as a pharmaceutical composition which inhibits secretion of gastric acid based on the said compound. Description is given of production of the new compound and a pharmaceutical composition based on the new compound, which can be used in medicine for treating such diseases as gastric ulcer, duodenal ulcer, stomal ulcer, gastroesophageal reflux, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux, endoscopy negative gastroesophageal reflux, gastroesophageal regurgitation, pharyngolaryngeal paresthesia, Barrett's esophagus, Non-steroidal anti-inflammatory drug (NSAID) induced ulcer, gastritis, gastric hemorrhage, gastrointestinal hemorrhage, peptic ulcer, bleeding ulcer, stress ulcer, gastric hyperchlorhydria, dyspepsia, gastroparesis, senile ulcer, intractable ulcer, heartburn, bruxism, stomach ache, heavy stomach or erosive gastritis.

EFFECT: increased effectiveness of composition and disease treatment.

7 cl, 6 tbl, 29 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new compounds of formula (I) , in which Ar is furanyl, thiophenyl, thiazolyl, pyridinyl; R1 is independently chosen from a group consisting of hydrogen, lower alkyl, lower alkoxy, halogen and nitro; R2 is independently chosen from a group consisting of hydrogen and halogen; R4 is hydroxyl or residue of pyrrolidine-2-carboxylic acid, piperidine-2-carboxylic acid or 1-aminocyclopentane carboxylic acid, bonded through a nitrogen atom of an amino acid residue; n is 0, 1, 2, 3, 4 or 5; m is 0, 1, 2, 3 or 4; p is 0, and s is 0, or to their pharmaceutically acceptable salts, under the condition that, the compound is not S-1- [5-(biphenyl-4-yloxymethyl)furan-2-carbonyl]pyrrolidin-2-carboxylic acid, 5-(biphenyl-4-yloxymethyl)furan-2-carboxylic acid, 3-(biphenyl-4-yloxymethyl)benzoic acid, 2-(biphenyl-3-yloxymethyl)benzoic acid, 4-(biphenyl-3-yloxymethyl)benzoic acid, 4-(biphenyl-4-yloxymethyl)benzoic acid, 5-(biphenyl-4-yloxymethyl)thiophene-2-carboxylic acid. Invention also relates to a pharmaceutical composition based on formula (I) compounds, which stimulates glycogen synthase activity.

EFFECT: wider range of use of the compounds.

27 cl, 34 ex, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns applications of a film for internal application containing triprolidine or its salt, or hydrate, as an active component of the remedy for awakening vigorous after sleeping. There is also disclosed method for treatment or prevention of sluggishness or somnolence in awakening after sleeping, the method that makes it possible for an individual to wake up vigorous after sleeping and the method ensuring falling asleep of an individual.

EFFECT: invention aims at development of the agent that makes it possible for an individual to wake up vigorous after sleeping.

19 cl, 5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products, particularly to pharmaceutical tuberculosis composition containing isoniazid conjugate with oxidised dextrane of molecular weight 35-60 kDa purified from free isoniasid and cytotoxic impurities, e.g. by spirit sedimentation at temperature 60-80°C. Additionally, the pharmaceutical composition contains a liposome-forming agent, e.g. phosphatidylcholine, pharmaceutically acceptable excipient, e.g. water for injection, saline or buffer solution. The component ratio is as follows: isoniasid conjugate with oxidised dextrane - 0.4-4.0 wt %, the liposome-forming agent - 0.1-1.0 wt %, the pharmaceutically acceptable excipient - to 100 wt %. The pharmaceutical composition represents nanoliposome emulsions of liposome size 150-800 nm.

EFFECT: lower hepatotoxicity and improved biocompatibility.

5 cl, 2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to a tetrazole compound with general formula I , where X3 and X4 are independently N and C, where one of X3 and X4 is certainly C; P is phenyl; m equals 1 or 2, where if m equals 1, R1 is bonded to P through a carbon atom on ring P in the meta-position of ring P relative the point at which P is bonded to X3, and if m equals 2, R1 is bonded to P through a carbon atom on ring P in positions 2 and 5 of ring P; R1 is halogen, C1-6alkyl, OC1-6alkyl or cyano group; X1 is C2-3alkyl, C2-3alkenyl, NR3, O, S, CR3R4, SO, SO2; X2 is a bond, CR3R4, O, S, NR3, SO, SO2; R3 and R4 are independently chosen from a group which consists of hydrogen, hydroxy, C1-6alkyl; Q is triazolyl, piperazinyl, or triazole or imidazole ring, condensed with a 6- or 7-member heterocyclic ring with one or two N atoms as heteroatoms; R is C1-6alkyl, C3-6cycloalkyl, pyridinyl, which can be substituted with a nitro, cyano, halogen or OC1-4alkyl group; phenyl, which can be substituted with a halogen, C1-4alkyl, OC1-4alkyl group; (CO)OC1-4alkyl; pyrimidinyl, which can be substituted with a OC1-4alkyl group; p equals 0, 1 or 2, or pharmaceutically acceptable salt or hydrate thereof.

EFFECT: invention also relates to method of inhibiting activity of mGluR5 receptors.

11 cl, 44 ex

FIELD: chemistry.

SUBSTANCE: invention relates to S-omeprazole strontium salt or hydrate thereof, to a method of preparing crystalline hydrate of S-omeprazole strontium salt, as well as to a pharmaceutical composition for preventing or treating disorders associated with gastric acid.

EFFECT: new S-omeprazole salt is obtained and described, which has high optical purity, thermal stability, solubility and nonhygroscopic.

22 cl, 11 ex, 5 tbl, 8 dwg

FIELD: chemistry.

SUBSTANCE: present invention relates to compounds with formula I: , in which: R1 is R6C(O)-, HC(O)-, R6SO2-, R6OC(O)-, (R6)2NC(O)-, R6-, (R6)2NC(O)C(O)-; R2 is a hydrogen atom, -CF3 or R8; R3 is a hydrogen atom or (C1-C4)aliphatic group-; R4 is -COOH; R5 is -CH2F or -CH2O-2,3,5,6- tetrafluorophenyl; R6 is (C1-C12)aliphatic or (C3-C10)cycloaliphatic group, (C6-C10)aryl-, (C3-C10)heterocyclyl-; and where R6 is substituted with up to 6 substitutes, independently chosen from R; R is a halogen atom, OR7 and -R7; R7 is (C1-C6)aliphatic group-, (C3-C10)cycloaliphatic group; R8 is (C1-C12)aliphatic- or (C3-C10)cycloaliphatic group; to a pharmaceutical composition with caspase-inhibiting activity, based on compound with formula I, to methods of treatment as well as to methods of inhibiting caspase-mediated functions and to a method of reducing production of IGIF or IFN-β. The invention also relates to a method of preserving cells, as well as to a method of producing compound with formula I.

EFFECT: new compounds are obtained and described, which can be used for treating diseases in the development of which caspase activity takes part.

34 cl, 4 tbl, 43 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, physiotherapy and neurology and can be applied in treatment of coupling osteochondrosis cases with radicular pain syndrome. It involves sequential cryo-exposure and ampli-pulse phoresis in spine coupling area paravertebrally to the most painful points and to one of legs along the direction of spinal nerve roots affected by pathological process, on the background of traditional medication therapy. Cryo-exposure is performed continuously at (-6)-(-12)°C for 5-12 minutes at one field. Milgamma solution is applied by ampli-pulse phoresis. Anode is positioned at waist area, and forked cathode is positioned at posteroexternal thigh surface.

EFFECT: enhanced efficiency of pain syndrome alleviation and waist motion span increase, simplified ampli-pulse phoresis procedure.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns correction of blood microvesicle level in arterial hypertension with impaired glucose tolerance. That is ensured by integrated treatment including graduated physical exercises, and introduction of Fosinopril in a dose 10 mg once in the morning and pioglitazone in a dose 30 mg once in the morning. Therapeutic course is at least 7 weeks.

EFFECT: complex of drug-free modalities and specific pharmacological preparations combined with empirically specified time of treatment provides maintained optimum microvesicle level that in turn allows considerably reducing risk of thrombotic complications in given group of patients.

1 ex

Up!